O	0	9	Switching
O	10	12	of
O	13	27	postmenopausal
O	28	33	women
O	34	38	with
O	39	48	endocrine
O	48	49	-
O	49	59	responsive
O	60	65	early
O	66	72	breast
O	73	79	cancer
O	80	82	to
O	83	94	anastrozole
O	95	100	after
O	101	102	2
O	103	108	years
O	108	109	'
O	110	118	adjuvant
O	119	128	tamoxifen
O	128	129	:
O	130	138	combined
O	139	146	results
O	147	149	of
O	150	155	ABCSG
O	156	161	trial
O	162	163	8
O	164	167	and
O	168	172	ARNO
O	173	175	95
O	176	181	trial
O	181	182	.

O	183	192	Tamoxifen
O	193	196	has
O	197	201	been
O	202	205	the
O	206	214	standard
O	215	223	adjuvant
O	224	233	treatment
O	234	237	for
O	238	252	postmenopausal
O	253	258	women
O	259	263	with
O	264	271	hormone
O	271	272	-
O	272	282	responsive
O	283	288	early
O	289	295	breast
O	296	302	cancer
O	303	306	for
O	307	311	more
O	312	316	than
O	317	319	20
O	320	325	years
O	325	326	.

O	327	334	However
O	334	335	,
O	336	339	the
O	340	345	third
O	345	346	-
O	346	356	generation
O	357	366	aromatase
O	367	376	inhibitor
O	377	388	anastrozole
O	389	392	has
O	393	399	proven
O	400	408	efficacy
O	409	412	and
O	413	425	tolerability
O	426	434	benefits
O	435	443	compared
O	444	448	with
O	449	458	tamoxifen
O	459	463	when
O	464	468	used
O	469	471	as
O	472	479	initial
O	480	488	adjuvant
O	489	496	therapy
O	496	497	.

O	498	500	We
O	501	512	investigate
O	513	520	whether
O	521	526	women
O	527	530	who
O	531	535	have
O	536	544	received
O	545	546	a
O	547	553	period
O	554	556	of
O	557	565	adjuvant
O	566	575	tamoxifen
O	576	581	would
O	582	589	benefit
O	590	594	from
O	595	600	being
O	601	609	switched
O	610	612	to
O	613	624	anastrozole
O	624	625	.

O	626	628	We
O	629	636	present
O	637	638	a
O	639	647	combined
O	648	656	analysis
O	657	659	of
O	660	664	data
O	665	669	from
O	670	673	two
O	674	685	prospective
O	685	686	,
O	687	698	multicentre
O	698	699	,
O	700	710	randomised
O	710	711	,
O	712	716	open
O	716	717	-
O	717	722	label
O	723	729	trials
O	730	734	with
O	735	741	nearly
O	742	751	identical
O	752	761	inclusion
O	762	770	criteria
O	770	771	.

B-eligibility	772	786	Postmenopausal
I-eligibility	787	792	women
I-eligibility	793	797	with
I-eligibility	798	805	hormone
I-eligibility	805	806	-
I-eligibility	806	815	sensitive
I-eligibility	816	821	early
I-eligibility	822	828	breast
I-eligibility	829	835	cancer
I-eligibility	836	839	who
I-eligibility	840	843	had
I-eligibility	844	853	completed
I-eligibility	854	855	2
I-eligibility	856	861	years
I-eligibility	861	862	'
I-eligibility	863	871	adjuvant
I-eligibility	872	876	oral
I-eligibility	877	886	tamoxifen
O	887	888	(
O	888	890	20
O	891	893	or
O	894	896	30
O	897	899	mg
O	900	905	daily
O	905	906	)
O	907	911	were
O	912	922	randomised
O	923	925	to
O	926	933	receive
O	934	935	1
O	936	938	mg
O	939	943	oral
B-intervention	944	955	anastrozole
O	956	957	(
O	957	958	n
O	958	959	=
B-intervention-participants	959	963	1618
O	963	964	)
O	965	967	or
O	968	970	20
O	971	973	or
O	974	976	30
O	977	979	mg
B-control	980	989	tamoxifen
O	990	991	(
O	991	992	n
O	992	993	=
B-control-participants	993	997	1606
O	997	998	)
O	999	1004	daily
O	1005	1008	for
O	1009	1012	the
O	1013	1022	remainder
O	1023	1025	of
O	1026	1031	their
O	1032	1040	adjuvant
O	1041	1048	therapy
O	1048	1049	.

O	1050	1053	The
O	1054	1061	primary
O	1062	1070	endpoint
O	1071	1074	was
B-outcome-Measure	1075	1080	event
I-outcome-Measure	1080	1081	-
I-outcome-Measure	1081	1085	free
I-outcome-Measure	1086	1094	survival
O	1094	1095	,
O	1096	1100	with
O	1101	1103	an
O	1104	1109	event
O	1110	1117	defined
O	1118	1120	as
O	1121	1126	local
O	1127	1129	or
O	1130	1137	distant
O	1138	1148	metastasis
O	1148	1149	,
O	1150	1152	or
O	1153	1166	contralateral
O	1167	1173	breast
O	1174	1180	cancer
O	1180	1181	.

O	1182	1190	Analysis
O	1191	1194	was
O	1195	1197	by
O	1198	1207	intention
O	1208	1210	to
O	1211	1216	treat
O	1216	1217	.

B-total-participants	1218	1222	3224
O	1223	1231	patients
O	1232	1236	were
O	1237	1245	included
O	1246	1248	in
O	1249	1257	analyses
O	1257	1258	.

O	1259	1261	At
O	1262	1263	a
O	1264	1270	median
O	1271	1277	follow
O	1277	1278	-
O	1278	1280	up
O	1281	1283	of
O	1284	1286	28
O	1287	1293	months
O	1293	1294	,
O	1295	1297	we
O	1298	1303	noted
O	1304	1305	a
O	1306	1308	40
O	1308	1309	%
O	1310	1318	decrease
O	1319	1321	in
O	1322	1325	the
B-outcome	1326	1330	risk
I-outcome	1331	1334	for
I-outcome	1335	1337	an
I-outcome	1338	1343	event
O	1344	1346	in
O	1347	1350	the
O	1351	1362	anastrozole
O	1363	1368	group
O	1369	1371	as
O	1372	1380	compared
O	1381	1385	with
O	1386	1389	the
O	1390	1399	tamoxifen
O	1400	1405	group
O	1406	1407	(
B-iv-bin-abs	1407	1409	67
O	1410	1416	events
O	1417	1421	with
O	1422	1433	anastrozole
O	1434	1436	vs
B-cv-bin-abs	1437	1440	110
O	1441	1445	with
O	1446	1455	tamoxifen
O	1455	1456	,
O	1457	1463	hazard
O	1464	1469	ratio
O	1470	1471	0
O	1471	1472	.
O	1472	1474	60
O	1474	1475	,
O	1476	1478	95
O	1478	1479	%
O	1480	1482	CI
O	1483	1484	0
O	1484	1485	.
O	1485	1487	44
O	1487	1488	-
O	1488	1489	0
O	1489	1490	.
O	1490	1492	81
O	1492	1493	,
O	1494	1495	p
O	1495	1496	=
O	1496	1497	0
O	1497	1498	.
O	1498	1502	0009
O	1502	1503	)
O	1503	1504	.

O	1505	1509	Both
O	1510	1515	study
O	1516	1526	treatments
O	1527	1531	were
B-outcome	1532	1536	well
I-outcome	1537	1546	tolerated
O	1546	1547	.

O	1548	1553	There
O	1554	1558	were
O	1559	1572	significantly
O	1573	1577	more
B-outcome	1578	1587	fractures
O	1588	1589	(
O	1589	1590	p
O	1590	1591	=
O	1591	1592	0
O	1592	1593	.
O	1593	1596	015
O	1596	1597	)
O	1598	1601	and
O	1602	1615	significantly
O	1616	1621	fewer
B-outcome	1622	1632	thromboses
O	1633	1634	(
O	1634	1635	p
O	1635	1636	=
O	1636	1637	0
O	1637	1638	.
O	1638	1641	034
O	1641	1642	)
O	1643	1645	in
O	1646	1654	patients
O	1655	1662	treated
O	1663	1667	with
O	1668	1679	anastrozole
O	1680	1684	than
O	1685	1687	in
O	1688	1693	those
O	1694	1696	on
O	1697	1706	tamoxifen
O	1706	1707	.

O	1708	1713	These
O	1714	1718	data
O	1719	1723	lend
O	1724	1731	support
O	1732	1734	to
O	1735	1736	a
O	1737	1743	switch
O	1744	1748	from
O	1749	1758	tamoxifen
O	1759	1761	to
O	1762	1773	anastrozole
O	1774	1776	in
O	1777	1785	patients
O	1786	1789	who
O	1790	1794	have
O	1795	1804	completed
O	1805	1806	2
O	1807	1812	years
O	1812	1813	'
O	1814	1822	adjuvant
O	1823	1832	tamoxifen
O	1832	1833	.
